Sparks commentary - Sareum Holdings

Healthcare

Sparks - Sareum Holdings

More on this equity
Sareum Holdings_resized
Sareum Holdings (AIM: SAR) restarts Phase II-enabling research
Published by Arron Aatkar, PhD

Sareum Holdings has announced that it has restarted the Phase II-enabling toxicology programme for SDC-1801, a selective TYK2/JAK1 inhibitor being developed as a potential treatment for a range of autoimmune diseases, with an initial focus on psoriasis. The company has appointed a leading CRO with extensive experience in long-term toxicology studies to conduct the programme. Prior to this, Sareum had completed preliminary pharmacokinetics work to assess tolerability and exposure levels across various formulations, allowing selection of a vehicle with some precedence in long-term studies. The dosing portion of this toxicology programme is due to conclude from mid-2026, with results expected by end-2026, which will be used to support the Phase II-enabling data package.

Latest